Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.32
$2.05
$0.84
$2.68
$1.03B1.054.38 million shs2.63 million shs
MannKind Corporation stock logo
MNKD
MannKind
$4.52
$3.52
$2.23
$6.51
$1.40B1.095.03 million shs9.19 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.52
$1.33
$0.98
$1.61
$1.15B1.482.92 million shs2.16 million shs
Verastem, Inc. stock logo
VSTM
Verastem
$4.50
$4.43
$3.43
$11.24
$395.43M0.292.79 million shs2.97 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.00%-9.02%+25.41%+45.91%+153.30%
MannKind Corporation stock logo
MNKD
MannKind
0.00%+9.10%+34.52%+80.80%+24.86%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-0.65%+4.11%+33.33%+13.43%
Verastem, Inc. stock logo
VSTM
Verastem
0.00%+19.05%+24.31%-20.07%-7.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.32
$2.05
$0.84
$2.68
$1.03B1.054.38 million shs2.63 million shs
MannKind Corporation stock logo
MNKD
MannKind
$4.52
$3.52
$2.23
$6.51
$1.40B1.095.03 million shs9.19 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.52
$1.33
$0.98
$1.61
$1.15B1.482.92 million shs2.16 million shs
Verastem, Inc. stock logo
VSTM
Verastem
$4.50
$4.43
$3.43
$11.24
$395.43M0.292.79 million shs2.97 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.00%-9.02%+25.41%+45.91%+153.30%
MannKind Corporation stock logo
MNKD
MannKind
0.00%+9.10%+34.52%+80.80%+24.86%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-0.65%+4.11%+33.33%+13.43%
Verastem, Inc. stock logo
VSTM
Verastem
0.00%+19.05%+24.31%-20.07%-7.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.33
Hold$4.5596.12% Upside
MannKind Corporation stock logo
MNKD
MannKind
2.60
Moderate Buy$8.9798.42% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.17
Hold$1.551.97% Upside
Verastem, Inc. stock logo
VSTM
Verastem
2.91
Moderate Buy$14.60224.44% Upside

Current Analyst Ratings Breakdown

Latest VSTM, MNKD, OPK, and LXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2026
Verastem, Inc. stock logo
VSTM
Verastem
Reiterated RatingBuy$18.00
6/24/2026
Verastem, Inc. stock logo
VSTM
Verastem
Reiterated RatingOutperform$15.00
6/24/2026
Verastem, Inc. stock logo
VSTM
Verastem
Reiterated RatingBuy$18.00
6/24/2026
Verastem, Inc. stock logo
VSTM
Verastem
Reiterated RatingBuy$18.00
6/23/2026
Verastem, Inc. stock logo
VSTM
Verastem
Lower Price TargetBuy$15.00 ➝ $8.00
6/18/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Reiterated RatingSell (D-)
6/17/2026
Verastem, Inc. stock logo
VSTM
Verastem
DowngradeSell (D-)Sell (E+)
6/1/2026
MannKind Corporation stock logo
MNKD
MannKind
Set Price TargetOverweight$11.00
5/26/2026
Verastem, Inc. stock logo
VSTM
Verastem
UpgradeSell (E+)Sell (D-)
5/18/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeSell (E+)Sell (D-)
5/14/2026
Verastem, Inc. stock logo
VSTM
Verastem
Lower Price TargetOutperform$16.00 ➝ $14.00
(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$49.80M20.69N/AN/A$0.30 per share7.73
MannKind Corporation stock logo
MNKD
MannKind
$348.97M4.00$0.06 per share73.05($0.17) per share-26.59
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M1.89N/AN/A$1.67 per share0.91
Verastem, Inc. stock logo
VSTM
Verastem
$30.91M12.79N/AN/A$0.74 per share6.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$5.86M-$0.07N/A37.67N/A-6.63%-11.21%-3.92%8/5/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-36.63%-16.78%-10.98%7/30/2026 (Estimated)
Verastem, Inc. stock logo
VSTM
Verastem
-$209.47M-$2.70N/AN/AN/A-391.17%-486.40%-91.56%8/6/2026 (Estimated)

Latest VSTM, MNKD, OPK, and LXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.08N/AN/AN/A$131.23 millionN/A
5/7/2026Q1 2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million
5/6/2026Q1 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.02-$0.05-$0.03-$0.05$105.38 million$90.17 million
4/28/2026Q1 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.07N/A-$0.07$130.51 million$124.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.24
18.80
18.77
MannKind Corporation stock logo
MNKD
MannKind
N/A
1.87
1.50
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17
Verastem, Inc. stock logo
VSTM
Verastem
0.89
3.04
3.00

Institutional Ownership

CompanyInstitutional Ownership
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Verastem, Inc. stock logo
VSTM
Verastem
88.37%

Insider Ownership

CompanyInsider Ownership
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
14.00%
MannKind Corporation stock logo
MNKD
MannKind
2.60%
OPKO Health, Inc. stock logo
OPK
OPKO Health
44.72%
Verastem, Inc. stock logo
VSTM
Verastem
1.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140444.20 million382.01 millionOptionable
MannKind Corporation stock logo
MNKD
MannKind
400308.95 million300.92 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million417.42 millionOptionable
Verastem, Inc. stock logo
VSTM
Verastem
5087.87 million86.17 millionOptionable

Recent News About These Companies

Here’s What RBC Capital Has to Say About Verastem (VSTM)
Verastem (VSTM) Gets a Buy from Alliance Global Partners
Verastem And The Biotech Side Of Penny Stocks

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.32 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$2.28 -0.04 (-1.94%)
As of 07/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

MannKind stock logo

MannKind NASDAQ:MNKD

$4.52 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$4.47 -0.05 (-1.04%)
As of 07/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.52 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$1.54 +0.02 (+1.05%)
As of 07/2/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Verastem stock logo

Verastem NASDAQ:VSTM

$4.50 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$4.49 -0.01 (-0.22%)
As of 07/2/2026 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.